Edward T Mathers
CIK 1328625 · EVP, Corporate Dev. & Venture · last filed 2026-08-11
Edward T Mathers is an EVP, Corporate Dev. & Venture who has filed 84 SEC Form 4 insider transactions across 19 companies since 2007. The most recent filing, for OKUR, was dated Aug 11, 2026. Across all open-market trades the lifetime net is +$47.2M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $434.6M across reported positions. 6 SEC filings were submitted jointly with Inozyme Pharma, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GLUE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
19TH FLOOR
NEW YORK, NY 10011
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OKUR | Director | 15,310 | $2.48 | $37.9K | $0 | 8 | 2026-08-11 |
| MBX | Director | 1,023,103 | $50.29 | $51.45M | $8.00M | 4 | 2026-06-05 |
| TRVI | Director | 948,948 | $12.51 | $11.87M | $0 | 9 | 2026-06-04 |
| RYTM | Director | 21,168 | $89.47 | $1.89M | $0 | 14 | 2026-03-16 |
| KRRO | 10%+ Owner | 1,297,893 | $12.02 | $15.60M | $3.30M | 2 | 2026-03-12 |
| SGP | 10%+ Owner | 6,035,038 | $29.91 | $180.51M | $15.00M | 1 | 2026-02-11 |
| NeueHealth, Inc. (BHG) Delisted | Director | 488,982 | $16.35 | $7.99M | -$24.5K | 6 | 2025-10-06 |
| SNTI | Director | — | $0.18 | — | $0 | 5 | 2025-06-27 |
| NeueHealth, Inc. (NEUE) Delisted | 10%+ Owner | — | $6.75 | — | $0 | 2 | 2024-10-03 |
| Inozyme Pharma, Inc. (INZY) Delisted | Director | — | $4.00 | — | $0 | 5 | 2024-06-20 |
| SVRA | 10%+ Owner | 24,471,264 | $4.52 | $110.61M | $1000.0K | 1 | 2023-07-19 |
| SYNLOGIC, INC. (SYBX) Delisted | Director | — | $0.69 | — | $0 | 8 | 2023-06-26 |
| OnKure Therapeutics, Inc. (RPHM) Delisted | Director | — | $18.20 | — | $0 | 3 | 2023-06-08 |
| Akouos, Inc. (AKUS) Delisted | Director | — | $13.29 | — | $0 | 3 | 2022-12-02 |
| MIRM | Director | — | $83.27 | — | $0 | 3 | 2022-06-06 |
| GLUE | 10%+ Owner | 5,973,296 | $10.48 | $62.60M | $19.95M | 1 | 2021-06-30 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | Director | — | — | — | $0 | 4 | 2020-04-03 |
| SYNLOGIC, INC. (MIRN) Delisted | Director | — | — | — | $0 | 1 | 2016-09-06 |
| MEDI | EVP, Corporate Dev. & Venture | — | $33.70 | — | $0 | 2 | 2007-06-19 |
Recent Filings
84 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-11 | OKUR | Grant (A) | — | $0 | EDGAR |
| 2026-06-08 | OKUR | Grant (A) | — | $0 | EDGAR |
| 2026-06-05 | MBX | Grant (A) | — | $0 | EDGAR |
| 2026-06-04 | TRVI | Grant (A) | — | $0 | EDGAR |
| 2026-03-16 | RYTM | Other (J) | +4,199 | $0 | EDGAR |
| 2026-03-12 | KRRO | Buy (P) | +207,100 | $2.30M | EDGAR |
| 2026-03-04 | RYTM | Other (J) | +4,198 | $0 | EDGAR |
| 2026-02-11 | SGP | Mixed | +6,035,038 | $15.00M | EDGAR |
| 2026-01-02 | OKUR | Grant (A) | +3,911 | $0 | EDGAR |
| 2025-10-06 | NeueHealth, Inc. (BHG) Delisted | Mixed | −299,787 | $10 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.